ClinicalTrials.gg
Enrolling by invitationNCT04008173ISACS-ARCHIVESUpdated May 1, 2026

The International Survey of Acute Coronary Syndromes-ARCHIVES

An observational study in Acute Coronary Syndrome, Unstable Angina Pectoris and Myocardial Infarction, sponsored by University of Bologna. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Bologna · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
130,000
Ages
18 Years and older
Sex
All
01

Study summary

ISACS ARCHIVES network is part of ISACS TC (NCT01218776) health care program. It is a collaborative network of research centers that support the rapid development of new scientific information and analytic tools. The ISACS ARCHIVES network assists health care providers, scientists, and policymakers seeking unbiased information about the outcomes, clinical effectiveness, safety, and appropriateness of health care items and services, particularly prescription medications and medical devices in acute coronary syndromes (ACS).

Read the detailed description

Purpose

ISACS-TC investigators may deposit to the ISACS ARCHIVES their registry data acquired prior to the first submitted date of ISACS-TC at ClinicalTrials.gov (October 7, 2010). Non- ISACS investigators with ACS data are welcome to deposit their data to the ISACS ARCHIVES as well. In this case the data may have been acquired prior or later than October 7, 2010. The data in the ISACS ARCHIVES will be catalogued and made available to the general research community. The ISACS ARCHIVES will use an established informatics infrastructure, hosted and managed by the ISACS TC (NCT01218776) and the Department of Electrical and Computer Engineering, University of California, Los Angeles, California, which will enable the sharing and use of data. The NIH. Gov. Registration number for the ISACS ARCHIVES will serve as the key for ACS related data submissions to the contact persons.

Applicable Data The ISACS ARCHIVES will accept only de-identified data from human subjects' studies on ACS (for a definition of human subjects see: https://humansubjects.nih.gov/glossary). This will include data from clinical trials, epidemiological surveys, and other types of studies involving human subjects. Databases with significant genomic data (e.g., genome-wide association studies, medical sequencing, molecular diagnostic assays), are expected to be deposited as well. Likewise, physical bio-samples can be included in the ISACS ARCHIVES.

Data Sharing Procedures Data submitted to the ISACS ARCHIVES must be de-identified by the investigator prior to submission. Submitted data will be subjected to algorithms that check for basic data accuracy. Any problematic data items will be summarized in a report and returned to the investigator for corrective action, if necessary, before data are accepted. Data will be made available for sharing with general research community 2 months after the deposit. This 2-month embargo period will provide study investigators with protected time to check for basic data accuracy. After the embargo, the data will be made available for sharing with the general research community. Investigators will be able to gain access to ISACS ARCHIVES data by submitting a data access request to ISACS TC (NCT01218776) contact persons. Data requests will be reviewed by an ISACS ARCHIVES Data Access Committee. The Department of Electrical and Computer Engineering, University of California, Los Angeles, California will collect data.

ISACS Data Archive Sharing The following is a summary of tasks and expectations related to submitting data to the ISACS ARCHIVES. The purpose of this summary is to provide an overview of data submission and data sharing via the ISACS ARCHIVES. This list only provides a summary of tasks.

Investigators are expected to:

  1. Collect Personally Identifiable Information (PII) from research subjects that will allow for the creation of the ISACS ARCHIVES Global Unique Identifier.
  2. Provide a de-identified subject ID, which is required for submission of data to the ISACS ARCHIVES.
  3. Complete and submit a Data-Sharing Agreement and Permission (DSAP) to ISACS TC (NCT01218776) contact persons.
  4. Review the ISACS TC data definition for the measures/experiments expected and define the project's data definition harmonized to that standard.
  5. Work with ISACS TC (NCT01218776) contact persons to define any undefined measures in accordance with ISACS TC practices.
  6. Specify the expected measures to be collected by the project in a summary table to be forwarded to the ISACS TC (NCT01218776) contact persons.
  7. Address any post submission quality assurance and quality control (QA/QC) checks that have been identified by the ISACS TC (NCT01218776).
  8. Create an ISACS ARCHIVES Library, linking a result from a publication, pipeline, or discovery of the data sent to ISACS ARCHIVES to its records for publications of results.

Policy Implementation ISACS ARCHIVES expects investigators and their institutions to provide basic plans for policy implementation

At present PI Study Investigators:

  • ISACS TC. International Survey of Acute Coronary Syndromes in Transitional Countries (ClinicalTrials.gov Identifier NCT01218776) from October 2010 to present. Contact person: Raffaele Bugiardini, MD University of Bologna email raffaele.bugiardini@unibo.it
  • HORACS: hospital registry for acute coronary syndrome in Serbia from January 2002 to September 2010. Contact person: Zorana Vasiljevic, MD Medical Faculty, University of Belgrade, email zoranav@eunet.rs
  • EMMACE-3 X. Long-term Follow-up of Health-Related Quality of Life in Patients With Acute Coronary Syndrome (ClinicalTrials.gov Identifier NCT01955525) during the period of 2011 to 2013. Contact person: Chris P Gale University of Leeds email c.p.gale@leeds.ac.uk

ISACS ARCHIVES Data Access Committee

  • Raffaele Bugiardini, University of Bologna (Principal Investigator)
  • Chris P Gale, University of Leeds
  • Olivia Manfrini, University of Bologna
  • Lina Badimon, Cardiovascular Research Institute (ICCC), CiberCV-Institute Carlos III, IIB-Sant Pau, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona
  • Mihaela van der Schaar, University of Cambridge

ISACS ARCHIVES Data Sharing Coordinators

  • Edina Cenko University of Bologna
  • Jinsung Yoon, Department of Electrical and Computer Engineering, University of California, Los Angeles

Sponsor University of Bologna

Inquiries

Please direct all inquiries to:

Principal Investigator: Raffaele Bugiardini, MD University of Bologna

02

Conditions studied

  • Acute Coronary Syndrome
  • Unstable Angina Pectoris
  • Myocardial Infarction
  • Coronary Disease
03

In context

Acute Coronary Syndrome

1,488 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

This study's planned enrollment of 130,000 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

University of Bologna is the lead sponsor of 158 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects admitted with a diagnosis of acute coronary syndromes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute coronary syndromes

Exclusion criteria

Exclusion Criteria:

  • under age or not able to give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
130,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Male

    Non-interventional patient registry

    Other: Non-interventional patient registry

  • Female

    Non-interventional patient registry

    Other: Non-interventional patient registry

  • Kidney Disease

    Non-interventional patient registry

    Other: Non-interventional patient registry

  • Diabetes

    Non-interventional patient registry

    Other: Non-interventional patient registry

  • Elderly

    Non-interventional patient registry

    Other: Non-interventional patient registry

Interventions

  • OtherNon-interventional patient registry

    Non-interventional patient registry

06

What researchers measure

Primary outcomes

  1. All causes death

    All causes death

    Time frame: 30 days

  2. All causes death

    All causes death

    Time frame: 6 months

  3. All causes death

    All causes death

    Time frame: 1 year

Secondary outcomes

  1. Cardiovascular death

    Cardiovascular death

    Time frame: up to 1 year

  2. Recurrent myocardial infarction

    A disorder characterized by signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease

    Time frame: up to 1 year

  3. Pharmacogenomics

    DNA sequence data to predict drug response and to inform drug discovery and development

    Time frame: up to 1 year

  4. Cardiovascular genetics of coronary heart disease

    Common variant genotyping for risk prediction

    Time frame: up to 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Bugiardini R, Yoon J, Kedev S, Stankovic G, Vasiljevic Z, Milicic D, Manfrini O, van der Schaar M, Gale CP, Badimon L, Cenko E. Prior Beta-Blocker Therapy for Hypertension and Sex-Based Differences in Heart Failure Among Patients With Incident Coronary Heart Disease. Hypertension. 2020 Sep;76(3):819-826. doi: 10.1161/HYPERTENSIONAHA.120.15323. Epub 2020 Jul 13. PubMed 32654558 ↗
  • Bugiardini R, Cenko E, Yoon J, van der Schaar M, Kedev S, Gale CP, Vasiljevic Z, Bergami M, Milicic D, Zdravkovic M, Krljanac G, Badimon L, Manfrini O. Concerns about the use of digoxin in acute coronary syndromes. Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):474-482. doi: 10.1093/ehjcvp/pvab055. PubMed 34251454 ↗
  • Vasiljevic Z, Scarpone M, Bergami M, Yoon J, van der Schaar M, Krljanac G, Asanin M, Davidovic G, Simovic S, Manfrini O, Mickovski-Katalina N, Badimon L, Cenko E, Bugiardini R. Smoking and sex differences in first manifestation of cardiovascular disease. Atherosclerosis. 2021 Aug;330:43-51. doi: 10.1016/j.atherosclerosis.2021.06.909. Epub 2021 Jun 26. PubMed 34233252 ↗
  • Bugiardini R, Yoon J, Mendieta G, Kedev S, Zdravkovic M, Vasiljevic Z, Milicic D, Manfrini O, van der Schaar M, Gale CP, Bergami M, Badimon L, Cenko E. Reduced Heart Failure and Mortality in Patients Receiving Statin Therapy Before Initial Acute Coronary Syndrome. J Am Coll Cardiol. 2022 May 24;79(20):2021-2033. doi: 10.1016/j.jacc.2022.03.354. PubMed 35589164 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04008173
Responsible party
Raffaele Bugiardini (Full Professor of Cardiology, University of Bologna) — Principal investigator
First posted
Jul 5, 2019
Start date
Jun 28, 2019
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 1, 2026

Study contacts

Raffaele Bugiardini, MD
principal investigator · University of Bologna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion